agoya University Pancreatic Tumor Board trial 08
Phase 2
Recruiting
- Conditions
- ocally advanced pancreatic cancer
- Registration Number
- JPRN-jRCTs041200054
- Lead Sponsor
- Kodera Yasuhiro
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
1.Locally advanced pancreatic cancer
2.Age 20<= and <=79
3.Performance status 0-1
Exclusion Criteria
1.distant metastasis
2.severe drug allergy
3.viable multiple primary cancer
4.gastrointestinal invasion
5.apparent infectious status
6.history of abdominal radiotherapy
7.pregnant or breastfeeding female
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 2-year survival rate
- Secondary Outcome Measures
Name Time Method Recurrence free survival, overall survival, pathological tumor reduction according to Evans grade, Tumor response defined by RECIST, rate of completion of preoperative therapy, rate of adverse effect, surgical morbidity, early tumor shrinkage, time to treatment failure
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular pathways are targeted by the NUPAT-08 phase II trial for locally advanced pancreatic cancer?
How does the JPRN-jRCTs041200054 intervention compare to FOLFIRINOX in LAPC progression-free survival?
Which biomarkers correlate with response to the NUPAT-08 therapy in BRCA-mutated pancreatic cancer?
What are the safety profiles of novel agents in the JPRN-jRCTs041200054 interventional trial for LAPC?
Are there combination therapies being evaluated with the NUPAT-08 regimen for KRAS-driven pancreatic tumors?